Managing Phosphate Can Be a Challenge in Patients with ESRD

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease. Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders.1 Continue on to learn more about the efficacy and safety profile of FOSRENOL.

Learn More

Efficacy and Safety of FOSRENOLStart Noncalcium Binder Therapy With FOSRENOL®

Invalid E-mail

X
You entered an invalid e-mail address Continue

Send to a Colleague

X

No personal information (including e-mail addresses) will be collected from this feature.